Sermorelin Peptide

Sermorelin is a synthetic peptide made up of 29 amino acids and represents the shortest functional fragment capable of activating growth hormone-releasing hormone (GHRH) receptors. It is an analog of GHRH (1-29 amide), designed to mimic the natural hormone and has been widely studied in research involving growth hormone deficiency.

Research into Sermorelin began in the early 1980s, where studies using GHRH (1-29) amide in animal models showed stimulation of the pituitary gland and increased growth-related activity. These findings led to continued investigation of Sermorelin and similar peptides in growth hormone-related studies.

Overview

Sermorelin is considered a GHRH analog containing the first 29 amino acids of the full 44-amino-acid hormone. It is believed to bind to GHRH receptors in the pituitary gland and stimulate the release of growth hormone (hGH). Despite its shorter structure, it appears to retain the core biological activity of GHRH, leading to increased levels of insulin-like growth factor-1 (IGF-1), which plays a key role in anabolic processes. Its half-life is relatively short, estimated at around 11–12 minutes.

One notable feature of Sermorelin is its receptor specificity, which may allow it to stimulate growth hormone release without significantly affecting other hormones such as cortisol, prolactin, insulin, glucose, or thyroid hormones.

Chemical Makeup

• Molecular Formula: C149H246N44O42S

• Molecular Weight: 3357.93 g/mol

• Other Known Titles: GRF 1-29

Sermorelin and GHRH Receptors

Sermorelin is believed to interact with GHRH receptors by initiating intracellular signaling pathways. Upon binding, it may stimulate adenylate cyclase activity, increasing cyclic adenosine monophosphate (cAMP) levels. This rise in cAMP may activate protein kinase A (PKA), which then triggers downstream cellular responses involved in growth hormone secretion.

Through this signaling pathway, Sermorelin is thought to promote the release of growth hormone from pituitary somatotroph cells, which may subsequently enhance the production of insulin-like growth factor-1 (IGF-1), supporting growth and metabolic functions.